Literature DB >> 17436244

Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype.

Reinhard Kalb1, Kornelia Neveling, Holger Hoehn, Hildegard Schneider, Yvonne Linka, Sat Dev Batish, Curtis Hunt, Marianne Berwick, Elsa Callen, Jordi Surralles, Jose A Casado, Juan Bueren, Angeles Dasi, Jean Soulier, Eliane Gluckman, C Michel Zwaan, Rosalina van Spaendonk, Gerard Pals, Johan P de Winter, Hans Joenje, Markus Grompe, Arleen D Auerbach, Helmut Hanenberg, Detlev Schindler.   

Abstract

FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a key role in DNA double-strand-type damage responses. Using complementation assays and immunoblotting, a consortium of American and European groups assigned 29 patients with FA from 23 families and 4 additional unrelated patients to complementation group FA-D2. This amounts to 3%-6% of FA-affected patients registered in various data sets. Malformations are frequent in FA-D2 patients, and hematological manifestations appear earlier and progress more rapidly when compared with all other patients combined (FA-non-D2) in the International Fanconi Anemia Registry. FANCD2 is flanked by two pseudogenes. Mutation analysis revealed the expected total of 66 mutated alleles, 34 of which result in aberrant splicing patterns. Many mutations are recurrent and have ethnic associations and shared allelic haplotypes. There were no biallelic null mutations; residual FANCD2 protein of both isotypes was observed in all available patient cell lines. These analyses suggest that, unlike the knockout mouse model, total absence of FANCD2 does not exist in FA-D2 patients, because of constraints on viable combinations of FANCD2 mutations. Although hypomorphic mutations arie involved, clinically, these patients have a relatively severe form of FA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17436244      PMCID: PMC1852747          DOI: 10.1086/517616

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  56 in total

1.  Positional cloning of a novel Fanconi anemia gene, FANCD2.

Authors:  C Timmers; T Taniguchi; J Hejna; C Reifsteck; L Lucas; D Bruun; M Thayer; B Cox; S Olson; A D D'Andrea; R Moses; M Grompe
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

2.  Alu insertion polymorphisms for the study of human genomic diversity.

Authors:  A M Roy-Engel; M L Carroll; E Vogel; R K Garber; S V Nguyen; A H Salem; M A Batzer; P L Deininger
Journal:  Genetics       Date:  2001-09       Impact factor: 4.562

3.  FANCE: the link between Fanconi anaemia complex assembly and activity.

Authors:  Paul Pace; Mark Johnson; Wu Meng Tan; Georgina Mosedale; Chelvin Sng; Maureen Hoatlin; Johan de Winter; Hans Joenje; Fanni Gergely; K J Patel
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 11.598

4.  S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51.

Authors:  Toshiyasu Taniguchi; Irene Garcia-Higuera; Paul R Andreassen; Richard C Gregory; Markus Grompe; Alan D D'Andrea
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

5.  Evolutionary clues to the molecular function of fanconi anemia genes.

Authors:  Eric Blom; Henri J van de Vrugt; Johan P de Winter; Fré Arwert; Hans Joenje
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

6.  Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool.

Authors:  Helmut Hanenberg; Sat Dev Batish; Karen E Pollok; Lydia Vieten; Peter C Verlander; Cordula Leurs; Ryan J Cooper; Kerstin Göttsche; Laura Haneline; D Wade Clapp; Stephan Lobitz; David A Williams; Arleen D Auerbach
Journal:  Exp Hematol       Date:  2002-05       Impact factor: 3.084

7.  The Caenorhabditis elegans FancD2 ortholog is required for survival following DNA damage.

Authors:  Florence Dequen; Jean-François St-Laurent; Steve N Gagnon; Madeleine Carreau; Serge Desnoyers
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2005-08       Impact factor: 2.231

Review 8.  The emerging genetic and molecular basis of Fanconi anaemia.

Authors:  H Joenje; K J Patel
Journal:  Nat Rev Genet       Date:  2001-06       Impact factor: 53.242

9.  Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia.

Authors:  Martin Digweed; Susanne Rothe; Ilja Demuth; Regina Scholz; Detlev Schindler; Markus Stumm; Markus Grompe; Andreas Jordan; Karl Sperling
Journal:  Carcinogenesis       Date:  2002-07       Impact factor: 4.944

10.  A novel diagnostic screen for defects in the Fanconi anemia pathway.

Authors:  Akiko Shimamura; Rocio Montes de Oca; John L Svenson; Nicholas Haining; Lisa A Moreau; David G Nathan; Alan D D'Andrea
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

View more
  56 in total

Review 1.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

2.  Mutations in Fanconi anemia genes and the risk of esophageal cancer.

Authors:  Mohammad R Akbari; Reza Malekzadeh; Pierre Lepage; David Roquis; Ali R Sadjadi; Karim Aghcheli; Abbas Yazdanbod; Ramin Shakeri; Jafar Bashiri; Masoud Sotoudeh; Akram Pourshams; Parviz Ghadirian; Steven A Narod
Journal:  Hum Genet       Date:  2011-01-30       Impact factor: 4.132

Review 3.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

Review 4.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.

Authors:  Mary Ellen Moynahan; Maria Jasin
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

5.  Patient-derived C-terminal mutation of FANCI causes protein mislocalization and reveals putative EDGE motif function in DNA repair.

Authors:  Luca Colnaghi; Mathew J K Jones; Xiomaris M Cotto-Rios; Detlev Schindler; Helmut Hanenberg; Tony T Huang
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

Review 6.  The Fanconi anemia ID2 complex: dueling saxes at the crossroads.

Authors:  Rebecca A Boisvert; Niall G Howlett
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.

Authors:  Alain Sarasin; Samuel Quentin; Nathalie Droin; Mourad Sahbatou; Véronique Saada; Nathalie Auger; Yannick Boursin; Philippe Dessen; Anna Raimbault; Vahid Asnafi; Jean-Luc Schmutz; Alain Taïeb; Carlos F M Menck; Filippo Rosselli; Laurianne Drieu La Rochelle; Caroline Robert; Flore Sicre de Fontbrune; Marie Sébert; Thierry Leblanc; Patricia Kannouche; Stéphane De Botton; Eric Solary; Jean Soulier
Journal:  Blood       Date:  2019-03-26       Impact factor: 22.113

8.  Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation.

Authors:  G Berger; E van den Berg; B Sikkema-Raddatz; K M Abbott; R J Sinke; L B Bungener; A B Mulder; E Vellenga
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

9.  Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage.

Authors:  Asmin Tulpule; M William Lensch; Justine D Miller; Karyn Austin; Alan D'Andrea; Thorsten M Schlaeger; Akiko Shimamura; George Q Daley
Journal:  Blood       Date:  2010-01-20       Impact factor: 22.113

10.  Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia.

Authors:  Settara C Chandrasekharappa; Francis P Lach; Danielle C Kimble; Aparna Kamat; Jamie K Teer; Frank X Donovan; Elizabeth Flynn; Shurjo K Sen; Supawat Thongthip; Erica Sanborn; Agata Smogorzewska; Arleen D Auerbach; Elaine A Ostrander
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.